Cure of advanced XXXX after correction of abnormal red blood cell deformability.

@entity859 @entity5 @entity19 @entity620 @entity14572 @entity786 @entity21923 @entity3600 @entity11748 @entity1391 @entity413 @entity2388
Chemotherapeutic efficacy is inversely related to @entity5 burden. A possible contributory factor in chemotherapy resistance is the occurrence of decreased red blood cell deformability in @entity19 with advanced @entity5 . Poorly deformable red blood cells may prevent adequate drug delivery to @entity5 cells. Two methods for improving red cell deformability were found in this study. The first involved treatment of @entity11748 -bearing @entity19 with red cell metabolic substrates, including @entity14572 , @entity859 , @entity413 , @entity21923 , and @entity620 . The combination of @entity14572 plus @entity21923 (3 mg of each drug in 0.5 cm3 @entity1391 -buffered saline) was most effective in restoring deformability to normal. Administration of an active chemotherapeutic agent ( @entity3600 or @entity786 ) also improved red cell deformability, with maximal restoration occurring 4--5 days after drug treatment. Standard and 50% of standard drug doses were equally effective in restoring deformability. The optimal therapy program for day 7 @entity11748 utilized @entity14572 plus @entity21923 given 10--15 min before @entity3600 15 mg/kg on day 7 and before @entity3600 30 mg/kg on day 12. This treatment yielded 44% cures, whereas @entity3600 alone, in identical dose and schedule, gave no cures. Median survival was 50 days for the @entity14572 - @entity2388 -treated @entity19 , as against 30 days for @entity3600 alone. Therefore, treatment with non-toxic doses of red blood cell metabolic substrates plus optimal timing of chemotherapy, two maneuvers that significantly increased red blood cell deformability, resulted in significant therapeutic benefit.
